NCT07275762招募中2 期
A Multicenter, Randomized, Double-blind, Double-dummy, Parallel-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of Y-4 Tablets in Chinese Patients With Postherpetic Neuralgia, Compared With Pregabalin Capsules
Neurodawn Pharmaceutical Co., Ltd.1 个研究点 分布在 1 个国家目标入组 160 人开始时间: 2026年2月2日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 160
- 试验地点
- 1
- 主要终点
- Evaluate the efficacy of Y-4 in patients with PHN by Change from baseline in Average Daily Pain Score (ADPS) for each group at week 13.
研究概览
简要总结
The goal of this clinical trial is to assess the efficacy and safety of Y-4 in patients with postherpetic neuralgia(PHN).
The main questions it aims to answer are: The efficacy and safety of Y-4 to treat PHN compared with pregabalin.
Researchers will analyze data from different groups, includes Y-4 group and pregabalin group , to see efficacy of Y-4 and If drug Y-4 is safe and tolerate in the patients with PHN.
Participants will :
- Take Y-4 (1w titration period: 75 mg pregabalin +18.75 mg riluzole, 12w fixed dose period: 150 mg pregabalin +37.5 mg riluzole, 1w drug withdraw period: 1w titration period: 75 mg pregabalin +18.75 mg riluzole) or pregabalin(75 mg for 1w titration period , 150 mg for 12w fixed dose period ,75 mg for 1w drug withdraw period) twice a day for 14 weeks after run-in period (placebo) lasting for 1 week.
- Visit the hospital according to the follow-up schedule agreed upon with your doctor. contact the research staff as soon as possible to reschedule when unable to attend the scheduled study visit.
- Use investigational products as directed by the doctor and undergo the related treatment.
- Inform their investigators of any changes in their health, including any side effects or symptoms, whether or not they believe these changes are related to the trial medication, as well as any new medications they are using or wish to use, or any changes in the dosage of medications they have already taking.
- Use reliable contraceptive methods , such as abstinence, intrauterine devices, double barrier methods (e.g., condom with spermicide or condom with a diaphragm containing spermicide), contraceptive implants, or oral contraceptives (except if the partner is infertile) during the study period and within one month after the study is completed.
- Must inform investigators immediately if they or their partner become pregnant during the study.
- Be sure to inform other doctors being consultant that you are participating in this clinical study.
- Restrict medication use and treatment during the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Able to understand and voluntarily sign the informed consent form.
- •Age ≥ 18 years, any gender.
- •Diagnosed with PHN, meaning pain persists for more than one month after the acute shingles rash has healed.
- •4. VAS score in SF-MPQ ≥ 40 mm of the last 24 hours during screening.
排除标准
- •1. Known previous allergy to the investigational products, rescue medication ingredients, other chemically similar drugs, or excipients.
- •2. During screening, individuals who have been clearly diagnosed with peripheral neuropathy or pain unrelated to PHN (including but not limited to those caused by cerebrovascular disease, Guillain-Barré syndrome, cervical or lumbar spine disorders, osteoarticular or tendon lesions, chronic kidney disease or uremia, thyroid disease, intracranial tumors, trauma, etc.) and are judged by the investigator to potentially confound the assessment of PHN.
- •3. During screen, suffer from a systemic disease that, in the opinion of the investigator, may affect the patient's participation in the study or affect the evaluation of the efficacy of PHN, including but not limited to:
- •Severe cardiopulmonary diseases, such as unstable angina, myocardial infarction, severe arrhythmia within 6 months prior to screening, NYHA cardiac function classification of grade III~IV at screening, hypertension (systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg at screening), recurrent asthma attacks, etc.;
- •Chronic digestive diseases, such as liver fibrosis, chronic active hepatitis, peptic ulcer, etc.;
- •Neuropsychiatric disorders, including epilepsy, recurrent dizziness or headache, cognitive impairment; Cerebrovascular disease (such as cerebral infarction) or recurrent transient ischemic attack within 6 months prior to screening;
- •History of malignant tumors within 5 years prior to screening (excluding cured basal cell carcinoma of the skin, carcinoma in situ and papillary thyroid carcinoma);
- •Presence of active infection, which, in the opinion of the investigator, is not suitable for entry into this study;
- •Diabetic patients with poor glycemic control (peritoneal venous blood glucose ≥11mmol/L at screening);
- •Suffering from immunocompromised diseases, such as systemic lupus erythematosus, acquired immunodeficiency syndrome, immunosuppressant therapy for autoimmune diseases.
- •4. During screening, situations may exist that investigators believe could affect pain assessment, such as if the affected skin area has a skin condition that may influence sensation.
- •5. Previously received nerve destruction for PHN, or underwent minimally invasive interventions (such as nerve blocks or neurostimulation), physical therapy (such as red light therapy), or traditional Chinese external treatments (such as acupuncture) within one week prior to screening.
- •6. Use prohibited drugs within the first 5 half-lives, or change the restricted drug dosage within the first 14 days.
- •7. Severe hematological, hepatatological, and renal function abnormalities at the time of screening, which meet any of the following laboratory test results: 1) Hematology: neutrophil count < 1.5×109/L, or platelet < 90×109/L, or hemoglobin <100g/L; 2) Liver function: ALT or AST > 2.5 times ULN; or TBIL > 1.5 times ULN; 3) Renal function: CrCL<60 mL/min/1.73 m2 (calculated based on Cockroft-Gault formula a); 4) Creatine kinase >2-fold ULN.
- •8. Participants already diagnosed with sleep apnea, or those with severe snoring and daytime sleepiness, as well as intermittent hypoxia.
- •9. Participants with a history of suicidal behavior, or those assessed to have suicidal tendencies using the Columbia-Suicide Severity Rating Scale (C-SSRS).
- •10.Hepatitis B surface antigen (HBsAg) positive and HBV-DNA titer >lower limit of reference value, or hepatitis C virus antibody (HCV-Ab) positive and HCV-DNA titer >lower limit of reference value, or human immunodeficiency virus antibody (HIV-Ab) positive, or serum Treponema pallidum-specific antibodies (TP-Ab) positiv eand rapid plasma reagin/toluidine red unheated serum test (RPR or TRUST) positive at screening.
- •11. Known drug abuse, or history of alcohol abuse within 1 year prior to screening, i.e., drinking more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of spirits with 40% alcohol or 150 mL of wine).
- •12. Pregnant or lactating females. 13.Male (or their partner) or female subjects have a fertility plan during the whole study period and within 1 month after the end of the study or are unwilling to take one or more non-drug contraceptive measures (such as condoms, intrauterine devices, etc.) during the study period.
- •14.Prior participation in any other clinical study of any other drug within 30 days prior to screening.
- •15.Engaging in high-altitude work, driving motor vehicles, or operating heavy machinery with associated risks during the study period.
- •16.Other conditions that are considered unsuitable by the investigator to participate in this clinical study.
研究组 & 干预措施
pregabalin group
Other
participants in this group will use pregabalin only
干预措施: Pregabalin (Drug)
Y-4 group
Experimental
Participants will take Y-4 tablets (1w titration period: 75 mg pregabalin +18.75 mg riluzole, 12w fixed dose period: 150 mg pregabalin +37.5 mg riluzole, 1w drug withdraw period: 1w titration period: 75 mg pregabalin +18.75 mg riluzole) , BID
干预措施: Y-4 tables (Drug)
结局指标
主要结局
Evaluate the efficacy of Y-4 in patients with PHN by Change from baseline in Average Daily Pain Score (ADPS) for each group at week 13.
时间窗: week 13
The average daily pain score is a commonly used clinical method for pain assessment. It converts the intensity of pain into numerical values (generally 0-10 points) based on patient self-reports or standardized scales. After recording multiple pain scores each day, an average is calculated to monitor changes in pain and treatment effects dynamically. The core function of pain scoring is to quantify the subjective experience of pain, helping doctors understand the degree of pain and adjust treatment plans. Commonly used scales include: Numeric Rating Scale (NRS): 0 points (no pain) to 10 points (worst pain imaginable).
次要结局
- Evaluate the efficacy of Y-4 in patients with PHN by ADPS response rate (i.e., proportion of patients with a ≥ 30% and ≥ 50% decrease in ADPS from baseline) at week 13(week 13)
- Evaluate the efficacy of Y-4 in patients with PHN by Change from baseline in Average Daily Pain Score (ADPS) for each group at week 1-12 and 14.(week 1-12 and 14)
- Evaluate the efficacy of Y-4 in patients with PHN by Change from baseline in Score of Average Daily Sleep Interference Score (ADSIS) in each group at week 1-14;(week 1-14)
- Evaluate the efficacy of Y-4 in patients with PHN by The proportion of patients grading ≤2 and ≤3 in each group using Patient Global Impression of Change scale (PGIC) at week 1, 3, 5, 7, 11, 13, 14.(week 1, 3, 5, 7, 11, 13, 14)
- Evaluate the efficacy of Y-4 in patients with PHN by Change from baseline in Simplified McGill Pain Questionnaire (SF-MPQ) in each group at week 1, 3, 5, 7, 9, 11, 13, 14 (single score and total score);(week 1, 3, 5, 7, 9, 11, 13, 14)
- Evaluate the efficacy of Y-4 in patients with PHN by Change from baseline in Hospital Anxiety and Depression Scale (HADS) at week 1, 3, 5, 7, 9, 11, 13, 14(week 1, 3, 5, 7, 9, 11, 13, 14)
- Evaluate the efficacy of Y-4 in patients with PHN by The amount of rescue medication acetaminophen tablets used by each group during the trial(the whole study（16 week）)
- Evaluate the safety of Y-4 in patients with PHN by The incidence of treatment-emergent adverse events (TEAE) in each group.(the whole study(16 week))
- Evaluate the safety of Y-4 in patients with PHN by rates of Significant Adverse Events.(the whole study(16 week))
- Evaluate the safety of Y-4 in patients with PHN by rates of Serious Adverse Events (SAE) after treatment.(the whole study(16 week))
- Evaluate the safety of Y-4 in patients with PHN by incidence of subject getting abnormal results of vital signs after treatment.(the whole study(16 week))
- Evaluate the safety of Y-4 in patients with PHN by incidence of subject getting abnormal results of physical examinations after treatment.(the whole study(16 week))
- Evaluate the safety of Y-4 in patients with PHN by incidence of subject getting abnormal results of 12-lead ECG after treatment.(the whole study(16 week))
- Evaluate the safety of Y-4 in patients with PHN by incidence of subject getting abnormal results of laboratory tests after treatment.(the whole study (16 week))
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease.AnthraxNCT07268612Emergent BioSolutions250
尚未招募
2 期
Efficacy, Safety, and Pharmacokinetics of LP-005 Injection in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)NCT07266155Longbio Pharma30
招募中
2 期
A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLCNCT07264816Sichuan Baili Pharmaceutical Co., Ltd.80
招募中
1 期
A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid ArthritisNCT07258849Eli Lilly and Company141
尚未招募
1 期
Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid TumorsNCT07272590Qilu Pharmaceutical Co., Ltd.290